Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. Issue 14 (6th May 2014)

• Record Type: Journal Article
• Authors: Nagaoki, Yuko; Imamura, Michio; Kawakami, Yoshiiku; Kan, Hiromi; Fujino, Hatsue; Fukuhara, Takayuki; Kobayashi, Tomoki; Ono, Atsushi; Nakahara, Takashi; Naeshiro, Noriaki; Urabe, Ayako; Yokoyama, Satoe; Miyaki, Daisuke; Murakami, Eisuke; Kawaoka, Tomokazu; Tsuge, Masataka; Hiramatsu, Akira; Aikata, Hiroshi; Takahashi, Shoichi; Hayes, C. Nelson; Ochi, Hidenori; Chayama, Kazuaki; Hiroshima Liver Study Group
• Is Part Of: Hepatology research. Volume 44:Issue 14(2014)
• Page Start: E447
• Page End: E454
• Publication Date: 2014-05-06
• Subjects: Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12336
• Languages: English
• ISSNs: 1386-6346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hepr12336-sec-0001" sec-type="section"> <title>Aim</title> <p>The predictive value of the recently identified interferon‐λ (IFNL)4 polymorphism on the outcome of telaprevir (TVR), pegylated interferon (PEG IFN) plus ribavirin (RBV) combination therapy for chronic hepatitis C is unknown.</p> </sec> <sec id="hepr12336-sec-0002" sec-type="section"> <title>Methods</title> <p>We assessed predictive factors for sustained virological response (SVR) for TVR, PEG IFN plus RBV combination therapy in 283 genotype 1 chronic hepatitis C patients. IFNL4 polymorphism ss469415590 was analyzed by Invader assay.</p> </sec> <sec id="hepr12336-sec-0003" sec-type="section"> <title>Results</title> <p>SVR rates for patients with IFNL4 TT/TT genotype were significantly higher than for those with the IFNL4 TT/ΔG or ΔG/ΔG genotypes (93% and 59%, respectively, <italic>P</italic> < 0.0001). In a multivariate regression analysis, prior treatment history (treatment‐naïve patients or patients who relapsed during prior treatment) (odds ratio [OR], 2.385; <italic>P</italic> = 0.028), rapid virological response (OR, 6.800; <italic>P</italic> < 0.0001) and ss469415590 TT/TT genotype (OR, 8.064; <italic>P</italic> < 0.0001) were identified as significant independent predictors for SVR. In patients with IFNL4 TT/ΔG or ΔG/ΔG genotypes, SVR rates for non‐RVR patients were significantly lower than RVR patients (22% and 75%, respectively, <italic>P</italic> < 0.0001).</p> </sec> <sec id="hepr12336-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Analysis of IFNL4 polymorphism is a valuable predictor in patients receiving TVR triple therapy.</p> </sec> </abstract>